Cover Image
市場調查報告書

CytomX Therapeutics, Inc.:產品平台分析

CytomX Therapeutics, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 321960
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
CytomX Therapeutics, Inc.:產品平台分析 CytomX Therapeutics, Inc. - Product Pipeline Review - 2016
出版日期: 2016年06月15日 內容資訊: 英文 42 Pages
簡介

CytomX Therapeutics, Inc.是提供各種發現、開發具有功能的抗體之方法的平台之生物科技企業。藉由該公司的平台,也可開發出對應癌症及發炎疾病等主要醫學性未滿足需求上的目標之多元化開發平台。

本報告提供CytomX Therapeutics, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

CytomX Therapeutics, Inc.的基本資料

CytomX Therapeutics, Inc.概要

  • 主要資訊
  • 企業資料

CytomX Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

CytomX Therapeutics, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

CytomX Therapeutics, Inc.:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

CytomX Therapeutics, Inc.:藥物簡介

  • CTX-023
  • CTX-033
  • CTX-1003
  • Monoclonal Antibody Conjugated for Cancer
  • Monoclonal Antibodies for Cancer
  • Monoclonal Antibody Conjugated for Oncology
  • Monoclonal Antibody to Antagonize Interleukin-6 Receptor for Inflammation
  • Monoclonal Antibody to Inhibit Glycoprotein-130 for Inflammation
  • Monoclonal Antibody to Target Notch Pathway for Cancer

CytomX Therapeutics, Inc.:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

CytomX Therapeutics, Inc.:最近的開發平台趨勢

CytomX Therapeutics, Inc.:暫停中的計劃

CytomX Therapeutics, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08066CDB

Summary

Global Markets Direct's, 'CytomX Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the CytomX Therapeutics, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CytomX Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of CytomX Therapeutics, Inc.
  • The report provides overview of CytomX Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses CytomX Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features CytomX Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate CytomX Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for CytomX Therapeutics, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding CytomX Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CytomX Therapeutics, Inc. Snapshot
    • CytomX Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • CytomX Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • CytomX Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • CytomX Therapeutics, Inc. - Pipeline Products Glance
    • CytomX Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • CytomX Therapeutics, Inc. - Drug Profiles
    • CTX-023
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTX-033
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTX-1003
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-072
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-2009
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target CD-71 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target ITGA-3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugated to Target CD3 and EGFR for Solid Tumor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates 1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates 2 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize CTLA4 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies 1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies 2 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates 3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize Interleukin-6 Receptor for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize PD-1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Glycoprotein-130 for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CytomX Therapeutics, Inc. - Pipeline Analysis
    • CytomX Therapeutics, Inc. - Pipeline Products by Target
    • CytomX Therapeutics, Inc. - Pipeline Products by Molecule Type
    • CytomX Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • CytomX Therapeutics, Inc. - Recent Pipeline Updates
  • CytomX Therapeutics, Inc. - Dormant Projects
  • CytomX Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CytomX Therapeutics, Inc., Key Information
  • CytomX Therapeutics, Inc., Key Facts
  • CytomX Therapeutics, Inc. - Pipeline by Indication, 2016
  • CytomX Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • CytomX Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • CytomX Therapeutics, Inc. - Preclinical, 2016
  • CytomX Therapeutics, Inc. - Discovery, 2016
  • CytomX Therapeutics, Inc. - Pipeline by Target, 2016
  • CytomX Therapeutics, Inc. - Pipeline by Molecule Type, 2016
  • CytomX Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016
  • CytomX Therapeutics, Inc. - Recent Pipeline Updates, 2016
  • CytomX Therapeutics, Inc. - Dormant Developmental Projects,2016

List of Figures

  • CytomX Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016
  • CytomX Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • CytomX Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • CytomX Therapeutics, Inc. - Pipeline by Top 10 Target, 2016
  • CytomX Therapeutics, Inc. - Pipeline by Molecule Type, 2016
  • CytomX Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top